510(k) · Cleared
Recalled · 2011Bio-Rad D-10 Dual Program
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Bio-Rad Laboratories, Inc. · LCP Assay, Glycosylated Hemoglobin
Cleared on Jun 9, 2004 as substantially equivalent to K984268 (Bio-Rad, 1998) and 1 other predicate after an 8-day review. Its family tree reaches back 2 generations to 1993. 1 later device descends from it. It has been recalled 2 times.
- Decided
- Jun 9, 2004
- Review
- 8 days
- Class
- Class II
- Product code
- LCP
- Recalls
- 2
- Predicates
- 2
Its longest line of descent runs back 2 generations to K926469 (1993). 4 ancestors in all, the oldest K924122 (1993). 1 later device descends from it, 1 citing it directly.
- Root · 2 generations backK926469 Variant (TM) Hemoglobin a 1C ProgramBio-Rad · 1993
- 1 generation backK984268 Variant II Hemoglobin A1C ProgramBio-Rad · 1998 · Recalled
- This deviceK041444 Bio-Rad D-10 Dual ProgramBio-Rad Laboratories, Inc. · 2004
- Descendant · cites it directly · 0 of its ownK060001 D-10 Hemoglobin A1C Program; D-10 Dual ProgramBio-Rad Laboratories, Inc. · 2006 · Recalled
Most influential descendants
Showing 1 of 1 · See all- K060001D-10 Hemoglobin A1C Program; D-10 Dual ProgramBio-Rad Laboratories, Inc. · 2006 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K926469 | Variant (TM) Hemoglobin a 1C Program | Bio-Rad | 1993 | — |
| −1 | K984268 | Variant II Hemoglobin A1C Program | Bio-Rad | 1998 | 2 |
| 0 (this device) | K041444 | Bio-Rad D-10 Dual Program | Bio-Rad Laboratories, Inc. | 2004 | — |
| +1 | K060001 | D-10 Hemoglobin A1C Program; D-10 Dual Program | Bio-Rad Laboratories, Inc. | 2006 | 1 |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1993 | 1 | 0 |
| 1999 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2006 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LCP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LCP device
- #1 K221326 Nova Allegro HbA1c Assay, Nova Allegro Analyzerscore 9.6 · 5 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (2)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K984268 | Variant II Hemoglobin A1C ProgramSummary page 1…s: HbA,,: VARIANTTM II Hemoglobin Al, Program Bio-Rad Laboratories [K984268; 12/17/98] HbA 2/F: VARIANT~M II 13-thalassemia Short Program… | 1998 |
| * | K991127 | Variant II B-ThalassemiaSummary page 1…HbA 2/F: VARIANT~M II 13-thalassemia Short Program Bio-Rad Laboratories [K991 127; 06/10/99] Presumptive Hemoglobin Identification:… | 1999 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K060001 | D-10 Hemoglobin A1C Program; D-10 Dual Program | 2006 | 0 |
Has anything in its family been recalled? (0 Class I)
Recalls of this device
| Date | Class | Recall | Root cause | Reason |
|---|---|---|---|---|
| Jul 11, 2011 | Not classified | Z-2889-2011 | Other | Reports of calibration failure and late retention time using Elution Buffer AA10434 and AA10435. |
| Nov 17, 2006 | Not classified | Z-0376-2007 | Other | The Diluent in the D-10 Dual Program Calibrator reorder packs is defective, and can cause early calibration failure or elevated control and sample recovery results. |
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 11 years and passes through 2 companies; a new generation was cleared every 5.7 years on median.
- 3 of the 4 ancestors have a recall of any class.
- Of its descendants, K060001 (Bio-Rad Laboratories, Inc., 2006) has gone furthest, with 0 descendants of its own.
- 5 other devices also cite its predicate K984268.
How does its category compare?
All LCP devicesLCP Assay, Glycosylated Hemoglobin: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · LCP
1in 2024
2026 to Oct 25, outlined.
Median 510(k) review, days · LCP
269in 2019
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · LCP
1in 2025
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · LCP
22in 2025
MAUDE reports naming product code LCP, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 7 | 133 | 1 | 5 |
| 2008 | 5 | 206 | 3 | 11 |
| 2009 | 6 | 158 | 6 | 15 |
| 2010 | 2 | — | 5 | 4 |
| 2011 | 10 | 176 | 51 | 27 |
| 2012 | 9 | 143 | 0 | 51 |
| 2013 | 2 | — | 4 | 193 |
| 2014 | 8 | 127 | 2 | 182 |
| 2015 | 3 | 239 | 2 | 64 |
| 2016 | 2 | — | 6 | 29 |
| 2017 | 5 | 218 | 1 | 149 |
| 2018 | 2 | — | 1 | 1,911 |
| 2019 | 4 | 269 | 0 | 114 |
| 2020 | 1 | — | 0 | 13 |
| 2021 | 0 | — | 0 | 7 |
| 2022 | 0 | — | 1 | 8 |
| 2023 | 2 | — | 0 | 27 |
| 2024 | 1 | — | 1 | 39 |
| 2025 | 0 | — | 1 | 22 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The Bio-Rad D-10TM Dual Program system is intended for the percent determination of hemoglobins A1c, A2, and F, and for the detection of abnormal hemoglobins in human whole blood using ion-exchange high performance liquid chromatography (HPLC). Measurement of the percent hemoglobin A1c is effective in monitoring long-term glucose control in individuals with diabetes mellitus, and measurement of the percent HbA2 and HbF is effective in long-term…
Read the full statement (126 words)
The Bio-Rad D-10TM Dual Program system is intended for the percent determination of hemoglobins A1c, A2, and F, and for the detection of abnormal hemoglobins in human whole blood using ion-exchange high performance liquid chromatography (HPLC).
Measurement of the percent hemoglobin A1c is effective in monitoring long-term glucose control in individuals with diabetes mellitus, and measurement of the percent HbA2 and HbF is effective in long-term monitoring of β-thalassemias (i.e., hereditary hemolytic anemias characterized by decreased synthesis of one or more types of abnormal hemoglobin polypeptide chains).
Detection of hemoglobin thalassemia variants such as hemoglobins S, C, D and E by HPLC is effective in presumptive identification of these variants. The Bio-Rad D-10 Dual Program is intended for Professional Use Only. For in vitro diagnostics use.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K041444 · printed Nov 6, 2026
Cite this page
510(k) Report. “K041444: Bio-Rad D-10 Dual Program.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K041444
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026